In its annual 'Measuring the Return from Pharmaceutical Innovation' report based on the top 20 pharma companies by 2020 R&D ...

Background Mechanical stress on the heart is commonly considered the sole stimulus explaining the synthesis and release of circulating natriuretic peptides and their derivatives. While one of the most ...

The company's peptide-based therapeutics offer the potential for targeted ... and has potential to transform the treatment paradigm for these disease indications. An NDA filing of icotrokinra for ...

Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb ... in a once daily pill could shift [the] treatment paradigm” for psoriasis. “The robust results seen to ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD studyTopline results from Phase ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor and is being studied in adults and adolescents 12 years of age and older with ...

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

This review highlights the key components of PDCs, including peptides, linkers, and payloads, and discusses the limitations hampering their developments. The integration of AI in PDC design and ...

Computational Mass Spectrometry, School of Life Sciences, Technical University of Munich, Freising 85354, Germany Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of ...